{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:36:04Z","timestamp":1785760564152,"version":"3.56.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To examine success rates of 5-fluorouracil, excision, and laser ablation as the initial and secondary management strategies for women with high-grade vaginal intraepithelial neoplasia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We conducted a retrospective case series of women referred to a single center for management of biopsy-proven, high-grade vaginal intraepithelial neoplasia between April 1994 and May 2016. Data including demographic characteristics, human papillomavirus risk factors, antecedent Pap cytology, concurrent or prior cervical and vulvar dysplasia, and treatment outcome including follow-up Pap cytology were recorded. All women were counseled on options of excision, laser ablation, or 5-fluorouracil, which was administered intravaginally according to a standardized regimen. Recurrence was defined as a biopsy showing any vaginal intraepithelial neoplasia diagnosis after primary treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Forty-seven patients were treated initially with 5-fluorouracil, 35 were treated with excision, and 22 were treated with laser ablation. Demographics were similar between groups. No recurrence was noted in 35 women treated with 5-fluorouracil (74%; 95% CI 62\u201387%), 20 treated with excision (57%; 95% CI 41\u201374%), and nine treated with laser ablation (41%; 95% CI 20\u201361%). Among 13 patients treated with 5-fluorouracil for recurrence, eight (62%) did not experience a second recurrence. Nine of 58 (16%) patients ever treated with 5-fluorouracil reported a side effect, most commonly irritation and dyspareunia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>5-fluorouracil was associated with a 74% success rate as the initial treatment modality for high-grade vaginal dysplasia. There is also a role for 5-fluorouracil in the management of recurrent or persistent high-grade vaginal intraepithelial neoplasia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000002311","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T19:13:36Z","timestamp":1511378016000},"page":"1237-1243","source":"Crossref","is-referenced-by-count":44,"title":["Topical 5-Fluorouracil for Women With High-Grade Vaginal Intraepithelial Neoplasia"],"prefix":"10.1097","volume":"130","author":[{"given":"Stephen","family":"Fiascone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison F.","family":"Vitonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0002-9378(77)90091-6","article-title":"An epidemiologic study of cancer of the cervix, vagina and vulva based on the Third National Cancer Survey in the United States","volume":"129","author":"Henson","year":"1977","journal-title":"Am J Obstet Gynecol"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1089\/jwh.2009.1570","article-title":"Update of HPV-associated female genital cancers in the United States, 1999\u20132004","volume":"18","author":"Watson","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/1097-0142(19910701)68:1<195::AID-CNCR2820680135>3.0.CO;2-L","article-title":"Natural history of vaginal intraepithelial neoplasia","volume":"68","author":"Aho","year":"1991","journal-title":"Cancer"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/01.AOG.0000435450.08980.de","article-title":"A clinicopathologic study of vaginal intraepithelial neoplasia","volume":"122","author":"Zeligs","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0002-9378(97)80018-X","article-title":"Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management","volume":"176","author":"Sillman","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20230711","first-page":"657","article-title":"Treatment of vaginal intraepithelial neoplasia with laser and topical 5-fluorouracil","volume":"73","author":"Krebs","year":"1989","journal-title":"Obstet Gynecol"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0090-8258(90)90180-S","article-title":"Vaginal intraepithelial neoplasia","volume":"36","author":"Audet-Lapointe","year":"1990","journal-title":"Gynecol Oncol"},{"key":"R8-20230711","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0002-9378(80)90256-2","article-title":"Vaginal intraepithelial neoplasia: biologic aspects and treatment with topical 5-fluorouracil and the carbon dioxide laser","volume":"138","author":"Petrilli","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"R9-20230711","first-page":"580","article-title":"Topical 5-fluorouracil treatment of vaginal intraepithelial neoplasia","volume":"58","author":"Caglar","year":"1981","journal-title":"Obstet Gynecol"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00006250-198003000-00016","article-title":"Treatment of vaginal dysplasia and carcinoma in situ with topical 5-fluorouracil","volume":"55","author":"Daly","year":"1980","journal-title":"Obstet Gynecol"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1471-0528.1985.tb01096.x","article-title":"Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia","volume":"92","author":"Kirwan","year":"1985","journal-title":"Br J Obstet Gynaecol"},{"key":"R12-20230711","first-page":"534","article-title":"Treatment with 5-fluorouracil of 35 patients with clinical or subclinical HPV infection of the vagina","volume":"17","author":"Stefanon","year":"1996","journal-title":"Eur J Gynaecol Oncol"},{"key":"R13-20230711","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0090-8258(75)90073-6","article-title":"Topical 5-fluorouracil in the treatment of vaginal carcinoma-in-situ","volume":"3","author":"Woodruff","year":"1975","journal-title":"Gynecol Oncol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0002-9378(79)90709-9","article-title":"Postirradiation squamous cell carcinoma in situ of the vagina: treatment by topical 20 percent 5-fluorouracil cream","volume":"135","author":"Piver","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"R15-20230711","first-page":"163","article-title":"Topical 5-fluorouracil in the treatment of intraepithelial neoplasia of the vagina","volume":"54","author":"Ballon","year":"1979","journal-title":"Obstet Gynecol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/gyno.2001.6401","article-title":"Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia","volume":"83","author":"Dodge","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00404-005-0022-1","article-title":"Vaginal intraepithelial neoplasia: clinical-therapeutic analysis of 33 cases","volume":"272","author":"Murta","year":"2005","journal-title":"Arch Gynecol Obstet"},{"key":"R18-20230711","first-page":"244","article-title":"Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms [in Spanish]","volume":"70","author":"Gonz\u00e1lez S\u00e1nchez","year":"2002","journal-title":"Ginecol Obstet Mex"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/LGT.0b013e3182730fec","article-title":"A cervical abnormality risk prediction model: can we use clinical information to predict which patients with ASCUS\/LSIL pap tests will develop CIN2\/3 or AIS?","volume":"17","author":"Charlton","year":"2013","journal-title":"J Low Genit Tract Dis"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201712000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T18:08:27Z","timestamp":1689098907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201712000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002311","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}